Stockreport
Assessing Mirum Pharmaceuticals (MIRM) Valuation After Strong Shareholder Returns And Rare Disease Pipeline Progress [Yahoo! Finance]
Last mirum pharmaceuticals, inc. - common stock earnings: 3/12 04:02 pm
Check Earnings Report
Mirum Pharmaceuticals (MIRM) has been drawing attention after posting annual revenue of US$521.3 million and a net loss of US$23.4 million, putting its rare disease portfolio and recent share performance under closer investor review. See our latest analysis for Mirum Pharmaceuticals. Mirum's recent annual numbers arrive after a strong year for shareholders, with a 116.34% 1 year total shareholder return, even as the 90 day share price return of 8.67% suggests momentum has cooled slightly in the short term. If Mirum's rare disease focus has your attention, this can be a good moment to scan for other specialised healthcare names using our screener of 32 healthcare AI stocks With Mirum trading at US$94.00 against an analyst price target of US$129.27 and an intrinsic value estimate suggesting a sizeable discount, the question is whether there is still a buying opportunity here or whether the market is already pricing in future growth. Most Popular Narrative: 11.8% Undervalued
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | MIRM | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
MIRM alerts
MIRM alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
MIRM alerts
High impacting Mirum Pharmaceuticals, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
MIRM
NEWS
NEWS
- Mirum Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026[Business Wire]
- Mirum Pharmaceuticals (MIRM) had its price target raised by Stifel Nicolaus from $125.00 to $130.00. They now have a "buy" rating on the stock.[MarketBeat]
- Mirum HDV Trial Success Adds New Late Stage Growth Option [Yahoo! Finance][Yahoo! Finance]
- Mirum Pharmaceuticals (MIRM) had its price target raised by Robert W. Baird from $95.00 to $112.00. They now have an "outperform" rating on the stock.[MarketBeat]
- Mirum Pharmaceuticals (MIRM) had its "buy" rating reaffirmed by HC Wainwright.[MarketBeat]
- More
MIRM
SEC Filings
SEC Filings
- 4/27/26 - Form SCHEDULE
- 4/27/26 - Form 8-K
- 4/24/26 - Form ARS
- MIRM's page on the SEC website
- More